Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIA Study of the Safety and Tolerability of the Use of Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis

Next Previous
Search
Trial Profile

Phase IIA Study of the Safety and Tolerability of the Use of Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imatinib (Primary)
  • Indications Diffuse scleroderma
  • Focus Therapeutic Use

Most Recent Events

  • 09 Jan 2018 Status changed from active, no longer recruiting to completed.
  • 25 Mar 2017 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last January 2013).
  • 15 Mar 2017 Results of proteomic analysis of sera collected from two phase II trial including this published in The Journal of Rheumatology

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top